Please upgrade your browser.
New investigation results, 'Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma...
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis.
The potential for metastasis makes recognition of CHRCC cells in cytologic preparations important for patient surveillance, management, and treatment.
Yusuke Sato of the University of Tokyo presented his work on discovering copy number changes in renal cell carcinoma, with the goal of identifying prognostic parameters for the disease as well as discovering novel molecular targets.
Life-extending drugs granted to a Stanway grandfather with advanced kidney cancer, are to be made available to thousands more patients.
Interview with Michael B. Kastan, M.D., Ph.D., director, Comprehensive Cancer Center, St. Jude Children's Research Hospital
Stand Up To Cancer (SU2C) announced today the second round of awards for its Innovative Research Grants Program (IRG), and named the 13 young scientists that will receive a combined total of $9.74 million over the grants three-year term to conduct high-risk/high-reward translational cancer research.
Dr. Chin talks about the field of cancer genomics, the challenges of translation, and her involvement in the The Cancer Genome Atlas project.
Mike Lawing: "...the Kidney Cancer Association is making waves in the effort to find a cure for kidney cancer. "
Want to learn why Cancer Discovery is being touted as a "must-read" for all researchers and clinician-scientists?
|Powered by NeonCRM|